序号 | 专利名 | 申请号 | 申请日 | 公开(公告)号 | 公开(公告)日 | 发明人 |
---|---|---|---|---|---|---|
1 | 精制塞曲司特的方法 | CN201010263925.7 | 2010-08-24 | CN101928215B | 2013-08-14 | 张宪生; 李东升 |
一种精制塞曲司特的方法,将粗品塞曲司特按1克∶5-20毫升加入在一次有机溶剂中,以1.2-2.0∶1摩尔比与弱碱性溶液于0-35℃下反应0.5-2小时,控制最终pH8.5-11.5,得到塞曲司特的盐溶液,经活性碳过滤后,再按1克∶1-5毫升加入在二次有机溶剂中,然后在0-35℃下搅拌,慢慢滴入盐酸溶液,析出结晶,控制反应液最终pH为3.5-7.5,过滤,水洗结晶,40-50℃真空干燥,得塞曲司特亮黄色结晶。本发明用于从粗品中提取塞曲司特精品,操作简便、周期短、质量易控、产品稳定性好。 | ||||||
2 | 具有NF-KB抑制作用的取代苯甲酸衍生物 | CN02802873.2 | 2002-09-11 | CN1505603A | 2004-06-16 | 铃木贤治; 布川阳一 |
下列通式(I)所表示的具有NF-κB阻碍作用的取代的苯甲酸衍生物(式中,R3,R4和R5各自独立地表示氢原子,碳数1~6的烷基或碳数1~6的烷氧基,R9和R10各自独立地表示氢原子,碳数1~6的烷基或碳数2~11的酰基);R2表示可以被取代的芳烃基或可以被取代的杂环基;X表示可以被酯化或酰胺化的羧基)。 | ||||||
3 | 可用作药物的具有至少一个羧基、磺基或酰胺基的2,5-或2,6-二取代的氢醌衍生物 | CN202180019787.4 | 2021-03-08 | CN115279730A | 2022-11-01 | J·鲍尔; O·马丁 |
本发明提供了新的式(I)的氢醌衍生物、制备方法以及治疗和/或预防例如自身免疫、免疫、风湿病、血管病症、眼科病症、纤维化病症、代谢和胃肠病症、神经炎性和神经退行性疾病、肿瘤和癌症相关病症、激素相关疾病和由病毒和细菌感染性疾病引起的免疫病症及其并发症的药物组合物和方法,其中R1为COOR4、(CH2)nCOOR4、SO3H、(CH2)nSO3H或CONH‑R10;R2和R3之一是H,另一个是R5。 | ||||||
4 | 大麻萜酚醌酸和其盐 | CN201980087878.4 | 2019-12-11 | CN113272271A | 2021-08-17 | E·穆诺兹布兰科; G·阿佩蒂诺 |
本申请涉及一种式(I)化合物或其式(II)药用盐,以及用于获得所述化合物的方法和用于获得所述盐的方法。另外,公开了所述式(I)化合物或其所述式(II)药用盐,其用作药物,具体地用作过氧化物酶体增殖物激活受体γ(PPARγ)激动剂。所述化合物适用于治疗或预防响应于PPARγ激动剂的疾病,如动脉粥样硬化、炎性肠病、类风湿性关节炎、肝纤维化、肾病、牛皮癣、皮肤伤口愈合、皮肤再生、胰腺炎、胃炎、神经退行性病症、神经炎性病症、硬皮病、癌症、高血压、肥胖症和II型糖尿病。 | ||||||
5 | 一种塞曲司特的生产方法 | CN201310729047.7 | 2013-12-26 | CN104744244A | 2015-07-01 | 张云 |
本发明涉及一种塞曲司特的生产方法,其特征是具体步骤如下:2,3,5-三甲基氢醌(I)和7-羟基苯庚酸(Ⅱ)溶于甲苯,加入D-樟脑-10-磺酸,在70℃下搅拌20h,反应液浓缩后,剩余物用10%三氯化铁水溶液氧化,经处理后,再层析得到塞曲司特。所述的一种塞曲司特的生产方法,其制造简单,生产成本低,产量高。 | ||||||
6 | 精制塞曲司特的方法 | CN201010263925.7 | 2010-08-24 | CN101928215A | 2010-12-29 | 张宪生; 李东升 |
一种精制塞曲司特的方法,将粗品塞曲司特按1克∶5-20毫升加入在一次有机溶剂中,以1.2-2.0∶1摩尔比与弱碱性溶液于0-35℃下反应0.5-2小时,控制最终pH8.5-11.5,得到塞曲司特的盐溶液,经活性碳过滤后,再按1克∶1-5毫升加入在二次有机溶剂中,然后在0-35℃下搅拌,慢慢滴入盐酸溶液,析出结晶,控制反应液最终pH为3.5-7.5,过滤,水洗结晶,40-50℃真空干燥,得塞曲司特亮黄色结晶。本发明用于从粗品中提取塞曲司特精品,操作简便、周期短、质量易控、产品稳定性好。 | ||||||
7 | 以苯基甲苯醌为有效成分的NF-kB抑制剂 | CN99800332.8 | 1999-03-19 | CN1262618A | 2000-08-09 | 布川阳一; 铃木贤治; 齐藤雅之 |
以通式(Ⅰ)(式中R1、R2和R3分别各自为氢、碳数1~5的烷基或碳数1~5的烷氧基,R4为氢、羟基甲基、烷基、或可被酯化或酰胺化的羧基,Z如式(A)所示,n为0~6)所示的苯醌衍生物或其氢醌体或其盐作为有效成分的NF-κB抑制剂。 | ||||||
8 | CANNABIGEROL QUINONE ACID AND SALTS THEREOF | PCT/EP2019/084764 | 2019-12-11 | WO2020120637A1 | 2020-06-18 | MUÑOZ BLANCO, Eduardo; APPENDINO, Giovanni |
The application relates to a compound of formula (I) or a pharmaceutical salt thereof of formula (II), as well as to a process to obtain said compound and a process to obtain said salt. Additionally disclosed is the compound of formula (I) or said pharmaceutical salt thereof of formula (II) for use as a medicament, in particular as a peroxisome proliferator-activated receptor gamma (PPAR γ ) agonist. The compounds are suitable for the treatment or prevention of a disease responsive to PPAR γ agonists such as atherosclerosis, inflammatory bowel diseases, rheumatoid arthritis, liver fibrosis, nephropathy, psoriasis, skin wound healing, skin regeneration, pancreatitis, gastritis, neurodegenerative disorders, neuroinflammatory disorders, scleroderma, cancer, hypertension, obesity and type II diabetes. |
||||||
9 | METHODS FOR DIAGNOSING AND TREATING CACHEXIA | PCT/CA2018/050639 | 2018-05-30 | WO2018218357A1 | 2018-12-06 | MCGEER, Patrick L.; LEE, Moonhee; MCGEER, Edith G.; KENNEDY, Krista |
A method of treating cachexia is provided. The method includes administering to a human in need thereof an effective amount of a complement inhibitor. The complement inhibitor may be a dimer of acetyl salicylic acid, including 5,5'-methylenebis(2-hydroxybenzoic acid), 4,4'-diacetoxy-1,1 biphenyl-3,3' dicarboxylic acid or a pharmaceutically acceptable salt thereof. The complement inhibitor may be aurin tricarboxylic acid, aurin quadracarboxylic acid, aurin pentacarboxylic acid, aurin hexacarboxylic acid, combinations thereof, and pharmaceutically acceptable salts thereof. The complement inhibitor may be an ester prodrug of the foregoing compounds. |
||||||
10 | PREVENTION AND REVERSAL OF INFLAMMATION INDUCED DNA DAMAGE | PCT/US2018/027786 | 2018-04-16 | WO2018194976A1 | 2018-10-25 | KELLEY, Mark R.; FEHRENBACHER, Jill |
Methods of reducing neuronal sensitivity, thereby reducing inflammation and chronic pain, are disclosed herein. Particularly disclosed are methods of administrating the apurinic/apyrimidinic endonuclease 1 redox factor 1 (APE1/Ref-1) inhibitor, APX3330, to enhance the DNA base excision repair (BER) pathway, thereby reducing neuronal sensitivity to inflammatory mediators and alleviating inflammatory or chronic pain. |
||||||
11 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | PCT/EP2021/055791 | 2021-03-08 | WO2021180655A1 | 2021-09-16 | BAUER, Jacques; MARTIN, Olivier |
The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R 1 is COOR 4, (CH 2 ) n COOR 4, SO 3 H, (CH 2 ) n SO 3 H or CONH-R 10; one of R 2 and R 3 is H and the other is R 5. |
||||||
12 | NF- kappa B INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT PHENYLMETHYL BENZOQUINONE | PCT/JP1999/001422 | 1999-03-19 | WO99048491A1 | 1999-09-30 | |
NF- kappa B inhibitors containing as the active ingredient benzoquinone derivatives represented by general formula (I), hydroquinone compounds thereof or salts of the same, wherein R1, R2 and R3 independently represent each H, C1-5 alkyl or C1-5 alkoxy; R4 represents H, hydroxy-methyl, alkyl or optionally esterified or amidated carboxy; Z is represented by formula (A); and n is from 0 to 6. | ||||||
13 | NOVEL QUINONOID DERIVATIVES OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF MALIGNANCIES | PCT/IL2008/000280 | 2008-03-05 | WO2008107878A1 | 2008-09-12 | MECHOULAM, Raphael; KOGAN, Natalya |
Novel cannabinoid-derived quinone derivatives (quinonoid derivatives) having a substituted hydroxyl group, pharmaceutical compositions comprising same and uses thereof as anti-proliferative agents, are provided. |
||||||
14 | STRAIN OF THE MICROORGANISM PENICILLIUM OXALICUM VAR. ARMENIACA AND ITS APPLICATION | PCT/CZ1998/000024 | 1998-05-20 | WO99050434A1 | 1999-10-07 | |
The strain of the microorganism Penicillium oxalicum var. Armeniaca CCM 8242 produces an anthraquinonyl carboxylic acid derivative of structural formula (I), which may be used as a colorant, especially as a food colorant or cosmetic colorant. | ||||||
15 | BICYCLIC QUINONE COMPOUNDS, THEIR PRODUCTION AND USE | PCT/JP1998/000422 | 1998-02-02 | WO98033758A1 | 1998-08-06 | |
A compound of formula (I), wherein R<1> and R<2> each represents a lower alkyl, or R<1> and R<2> may be bonded together to form a ring; X represents a spacer of which the number of atoms constituting the principal chain is 1 to 15; Y represents an acyl, or a hydroxy, an amino or an aromatic group, each of which may be substituted; and ring A represents a 5- to 8-membered ring which may be further substituted apart from -X-Y, or a salt thereof is useful as a pharmaceutical composition for preventing or treating disease related to mitochondrial dysfunction. | ||||||
16 | QUINONE BACTERIAL INHIBITORS | PCT/GB1997001702 | 1997-06-25 | WO1997049662A1 | 1997-12-31 | THE UNIVERSITY OF SHEFFIELD |
A compound as an inhibitor of bacteria comprising a quinone fragment, a process for the preparation thereof, its composition and a process for the preparation thereof and use in combatting bacteria, in particular vitamin K dependent bacteria. | ||||||
17 | 쿠마린계 또는 나프토퀴논계 화합물, 이의 제조 방법, 및 용도 | KR1020160097031 | 2016-07-29 | KR101843144B1 | 2018-05-14 | 황은숙; 차바시리와린쏜; 하이라니리타; 김효경 |
쿠마린계또는나프토퀴논계화합물, 이의입체이성질체, 유도체, 또는약학적으로허용가능한염을제공한다. 상기쿠마린계또는나프토퀴논계화합물, 이의입체이성질체, 유도체, 또는약학적으로허용가능한염은항-비만효과를가지므로, 비만을포함한대사성질환의예방또는치료제로서사용할수 있다. | ||||||
18 | 아미드계 유도체 화합물, 이의 생산 방법 및 용도 | KR1020150083670 | 2015-06-12 | KR101721665B1 | 2017-03-30 | 오동찬; 김성환; 신종헌; 이상국 |
아미드계유도체화합물, 이의생산방법, 및용도를제공한다. 상기화합물은항암활성을가지므로, 상기화합물은암을예방또는치료하는데사용할수 있다. | ||||||
19 | 아미드계 유도체 화합물, 이의 생산 방법 및 용도 | KR1020150083670 | 2015-06-12 | KR1020160146414A | 2016-12-21 | 오동찬; 김성환; 신종헌; 이상국 |
아미드계유도체화합물, 이의생산방법, 및용도를제공한다. 상기화합물은항암활성을가지므로, 상기화합물은암을예방또는치료하는데사용할수 있다. | ||||||
20 | 퀴논 유도체의 제조방법 | KR1019850005541 | 1985-07-31 | KR1019860001779A | 1986-03-22 | 데라오신지; 마끼요시다까 |
내용 없음 |